H.C. Wainwright lowered the firm’s price target on Reviva Pharmaceuticals (RVPH) to $4 from $11 and keeps a Buy rating on the shares. The firm cites the company’s two “highly dilutive” financing transactions in June and September for the target cut.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVPH: